The hidden third: improving outcome in treatment-resistant depression
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Treatment-resistant depression (TRD) presents many challenges for both patients and physicians. This review aims to evaluate the current status of the field of TRD and reflects the main findings of a consensus meeting held in September 2009. Literature searches were also conducted using PubMed and EMBASE. Abstracts of the retrieved articles were reviewed independently by the authors for inclusion. Evaluation of the clinical evidence in TRD is complicated by the absence of a validated definition, and there is a need to move away from traditional definitions of remission based on severity of symptoms to one that includes normalisation of functioning. One potential way of improving treatment of TRD is through the use of predictive biomarkers and clinical variables. The advent of new treatments may also help by focusing on neurotransmitters other than serotonin. Strategies such as the switching of antidepressants, use of combination therapy with lithium, atypical antipsychotics and other pharmacological agents can improve outcomes, and techniques such as deep brain stimulation and vagus nerve stimulation have shown promising early results. Despite consistent advances in the pharmacotherapy of mood disorders in the last decade, high rates of TRD are still a challenging aspect of overall management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Depression, chronic diseases, and decrements in health: results from the World Health Surveys
Moussavi, S., Chatterji, S., Verdes, E., Tandon, A., Patel, V., & Ustun, B. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61415-9 · Cited by 4,070
Deep Brain Stimulation for Treatment-Resistant Depression
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., Schwalb, J. M., & Kennedy, S. H. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.014 · Cited by 4,059 · cited 2×
“…patients treated with DBS of the ventral caudate/ventral striatum and subcallosal cingulate white matter, respectively, and 50% after 12 months of treatment in those who received DBS of the nucleus accumbens (Mayberg et al., 2005; Lozano et al., 2008; Malone et al., 2009; Bewernick et al., 2010).”
BackgroundTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 2×
“Even in patients who receive adequate treatment with an antidepressant, a large percentage of depressive episodes are associated with some degree of treatment resistance (Souery et al., 1999; Rush et al., 2006; Trivedi et al., 2006, 2009).”
BackgroundInflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848 · cited 4×
“Patients with depression have been found to have increased levels of inflammatory cytokines in their circulation, which can interact with neurotransmitter and neuroendocrine pathways (Miller et al., 2009).”
BackgroundInfluentialA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Genetic Epidemiology of Major Depression: Review and Meta-Analysis
Sullivan, P. F., Neale, M. C., & Kendler, K. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.10.1552 · Cited by 3,431 · cited 5×
“Indeed, MDD heritability of 37% has been demonstrated in a meta-analysis of five twin studies (Sullivan et al., 2000), whereas a meta-analysis of five family studies has shown a two- to three-fold increase in lifetime risk of developing MDD among first-degree relatives (Sullivan et al.”
BackgroundInfluentialThe Functioning and Well-being of Depressed Patients: Results From the Medical Outcomes Study
Wells, K. B. (1989) · JAMA · doi:10.1001/jama.1989.03430070062031 · Cited by 2,130 · cited 1×
“The clinical importance of these figures is underscored by the fact that incomplete recovery or partial remission from a depressive episode is associated with serious personal, economic and psychosocial morbidity (Wells et al., 1989; Donohue and Pincus, 2007; Moussavi et al., 2007).”
Background(2003) · The Lancet · doi:10.1016/s0140-6736(03)12705-5 · Cited by 1,706 · cited 1×
“Moreover, prodromal symptoms have been identified in patients with unipolar and bipolar depression, and recognition of such symptoms by patients and their physicians may allow effective intervention to prevent relapse (Geddes, 2003).”
BackgroundSize and burden of mental disorders in Europe—a critical review and appraisal of 27 studies
Wittchen, H.-U., & Jacobi, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.012 · Cited by 1,503 · cited 1×
“Importantly, data on the incidence of major depressive disorder (MDD) in Europe, particularly treatment-resistant depression (TRD), are limited, although MDD is one of the most prevalent mental disorders (Figure 1) (Wittchen and Jacobi, 2005).”
BackgroundDiagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 6×
“There are now several new brain stimulation methods that provide alternatives to ECT.”
MethodInfluentialAnderson, I. M. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00092-0 · Cited by 940
Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Treatment-Resistant Depression
Malone, D. A., Dougherty, D. D., Rezai, A. R., Carpenter, L. L., Friehs, G. M., Eskandar, E. N., Rauch, S. L., Rasmussen, S. A., Machado, A. G., Kubu, C. S., et al. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.029 · Cited by 897 · cited 4×
“Recently, this method has been demonstrated to have some effects in even the most treatment-resistant cases of depression in three independent, small studies (Malone et al., 2009; Bewernick et al., 2010).”
BackgroundMethodInfluentialBewernick, B. H., Hurlemann, R., Matusch, A., Kayser, S., Grubert, C., Hadrysiewicz, B., Axmacher, N., Lemke, M., Cooper-Mahkorn, D., Cohen, M. X., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.013 · Cited by 865 · cited 4×
“Recently, this method has been demonstrated to have some effects in even the most treatment-resistant cases of depression in three independent, small studies (Malone et al., 2009; Bewernick et al., 2010).”
BackgroundMethodInfluentialSelf-citationSirey, J. A., Bruce, M. L., Alexopoulos, G. S., Perlick, D. A., Friedman, S. J., & Meyers, B. S. (2001) · Psychiatric Services · doi:10.1176/appi.ps.52.12.1615 · Cited by 796 · cited 1×
“For example, perceived stigma and the patient’s view of depression can affect adherence (Sirey et al., 2001), whereas the nature of depression itself works against treatment success.”
BackgroundMüller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Sackeim, H. A., Haskett, R. F., Mulsant, B. H., Thase, M. E., Mann, J. J., Pettinati, H. M., Greenberg, R. M., Crowe, R. R., Cooper, T. B., & Prudic, J. (2001) · JAMA · doi:10.1001/jama.285.10.1299 · Cited by 686 · cited 1×
“In order to minimise relapse, the use of pharmacotherapy or maintenance ECT may be beneficial (Wijkstra et al., 2000; McCall, 2001; Sackeim et al., 2001).”
BackgroundSouery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0713 · Cited by 521
Self-citationMarcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., Trivedi, M. H., Thase, M. E., & Berman, R. M. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816774f9 · Cited by 518
Overview of the Genetics of Major Depressive Disorder
Lohoff, F. W. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0150-6 · Cited by 498 · cited 4×
“It is postulated that multiple genetic variants in conjunction with environmental factors are responsible for the development of MDD (Sullivan et al., 2000; Lohoff, 2010), and large-scale studies are required to further investigate the complex phenotype of MDD and identify pathways in its development.”
BackgroundInfluentialLam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431 · cited 2×
“An alternative to combining two antidepressants is to augment antidepressant therapy with a different drug, and such augmentation strategies are among the best validated pharmacological treatments for TRD (Lam et al., 2009).”
BackgroundA Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
George, M. S., Rush, A. J., Marangell, L. B., Sackeim, H. A., Brannan, S. K., Davis, S. M., Howland, R., Kling, M. A., Moreno, F., Rittberg, B., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.028 · Cited by 372 · cited 2×
“, 2005b) compared with patients who received only treatment as usual (George et al., 2005).”
ResultNutt, D., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, P. L., Carrasco, J. L., & Stahl, S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106069938 · Cited by 366 · cited 3×
“Thus, there is a pattern of symptoms inadequately addressed by serotonergic antidepressants, suggesting treatments that enhance noradrenergic or dopaminergic activity may be more appropriate to certain types of TRD, such as depression with comorbid anxiety disorders or patients with predominant symptoms of fatigue (Nu…”
BackgroundInfluentialSelf-citationThe Maudsley Prescribing Guidelines
Taylor, D., Paton, C., & Kerwin, R. (2007) · doi:10.1201/b21605 · Cited by 366
Blier, P., Ward, H. E., Tremblay, P., Laberge, L., Hébert, C., & Bergeron, R. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020186 · Cited by 316 · cited 1×
“(Blier et al., 2010).”
Psychological therapies for generalised anxiety disorder
Hunot, V., Churchill, R., Teixeira, V., & Silva de Lima, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001848.pub4 · Cited by 315 · cited 1×
“In addition to a role in treatment of depression, psychotherapy may also be of value in the treatment of comorbidities, particularly anxiety disorders (Hunot et al., 2007; Schoevers et al., 2008).”
BackgroundBerman, R. M., Fava, M., Thase, M. E., Trivedi, M. H., Swanink, R., McQuade, R. D., Carson, W. H., Adson, D., Taylor, L., Hazel, J., et al. (2009) · CNS Spectrums · doi:10.1017/s1092852900020216 · Cited by 260 · cited 1×
“Data supporting the efficacy of aripiprazole augmentation in patients with TRD comes from three double-blind, placebo-controlled, 14-week trials (Berman et al., 2007; Marcus et al., 2008; Berman et al., 2009).”
MethodAltshuler, L. L., Bauer, M., Frye, M. A., Gitlin, M. J., Mintz, J., Szuba, M. P., Leight, K. L., & Whybrow, P. C. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1617 · Cited by 250 · cited 2×
“Although the efficacy of T3 augmentation of TCAs is more established (Aronson et al., 1996; Altshuler et al., 2001; Carvalho et al., 2009; Connolly and Thase, 2011), evidence for the efficacy of T3 augmentation of SSRIs is more disparate based on the available evidence (Nierenberg et al.”
BackgroundCrismon, M. L., Trivedi, M., Pigott, T. A., Rush, A. J., Hirschfeld, R. M. A., Kahn, D. A., DeBattista, C., Nelson, J. C., Nierenberg, A. A., Sackeim, H. A., et al. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0302 · Cited by 250 · cited 3×
“TMAP – MDD without psychotic features (Crismon et al., 1999) • A clinical psychopharmacology consultation should be considered in treatment-resistant patients • After two different first-line monotherapy antidepressants, a third monotherapy from a different class or a combination of an SSRI and a TCA should be conside…”
BackgroundInfluentialA prospective follow-up of patients with bipolar and primary unipolar affective disorder
Winokur, G. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820180059006 · Cited by 249 · cited 1×
“Indeed, 17–21% of patients suffering from major depression have a poor outcome after 2 years, and 8–13% have a poor outcome even after 5 years of treatment (Winokur et al., 1993).”
BackgroundCrossley, N. A., & Bauer, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0617 · Cited by 246
An update on regional brain volume differences associated with mood disorders
Campbell, S., & MacQueen, G. (2006) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000194371.47685.f2 · Cited by 198 · cited 1×
“Brain imaging studies show clear regional effects in MDD, with a small hippocampus and amygdala reported in some, although not all, imaging studies (Campbell and MacQueen, 2006).”
BackgroundPartial remission, residual symptoms, and relapse in depression
Paykel, E. S. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.4/espaykel · Cited by 194
Parikh, S. V., Segal, Z. V., Grigoriadis, S., Ravindran, A. V., Kennedy, S. H., Lam, R. W., & Patten, S. B. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.042 · Cited by 183 · cited 2×
“evidence to ascertain its superiority or inferiority compared with CBT or pharmacological interventions (Parikh et al., 2009).”
BackgroundBarbosa, L., Berk, M., & Vorster, M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0407 · Cited by 165
Daban, C., Martinez-Aran, A., Cruz, N., & Vieta, E. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.02.012 · Cited by 163
Mendlewicz, J. (2009) · The World Journal of Biological Psychiatry · doi:10.3109/15622970802503086 · Cited by 143 · cited 4×
“Circadian gene mutations are associated with circadian rhythm disorders (Mendlewicz, 2009b) and such disorders have been observed in patients with depression (Monteleone and Maj, 2008), which suggests a shared aetiology between circadian disruption and depression (Mendlewicz, 2009b).”
BackgroundInfluentialOnset of action of escitalopram compared with other antidepressants: results of a pooled analysis
Kasper, S., Spadone, C., Verpillat, P., & Angst, J. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000194375.42589.c3 · Cited by 100
Self-citationRemission in depressed outpatients: More than just symptom resolution?
Zimmerman, M., McGlinchey, J. B., Posternak, M. A., Friedman, M., Boerescu, D., & Attiullah, N. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.09.004 · Cited by 98 · cited 2×
“…part of the Methods to Improve Diagnostic Assessment and Services (MIDAS) project, the association between level of severity of depressive symptoms and functional impairment was evaluated for its ability to predict patients’ subjective evaluation of their remission status (Zimmerman et al., 2008).”
MethodTolerability of Serotonin Norepinephrine Reuptake Inhibitor Antidepressants
Montgomery, S. A. (2008) · CNS Spectrums · doi:10.1017/s1092852900028297 · Cited by 65
Research works printed but not linked: 113
- 10.1002/da.20589 · DOI · Paper page
- 10.1177/0269881107088441 · DOI · Paper page
- 10.1016/j.euroneuro.2008.10.003 · DOI
- 10.1017/S1092852900017430 · DOI
- 10.1001/archpsyc.1996.01830090090013 · DOI · Paper page
- Arroll B, 2009, Cochrane Database Syst Rev, CD007954
- Baldessarini R (2001) Goodman & Gilman’s The Pharmacological Basis of Therapeutics, Hardman J, Limbird L, Gilman A (eds). New York: McGraw Hill, pp. 447–483.
- Baldessarini R, Tarazi F (2001) Goodman & Gilman’s The Pharmacological Basis of Therapeutics, Hardman J, Limbird L, Gilman A (eds). New York: McGraw Hill, pp. 485–520.
- 10.1080/15622970701227829 · DOI · Paper page
- Bauer M, 2002, World J Biol Psychiatry, 3, 69, 10.3109/15622970209150605 · DOI · Paper page
- 10.3109/15622970209150599 · DOI · Paper page
- 10.4088/JCP.v68n0604 · DOI · Paper page
- 10.1097/YCO.0b013e32831be9ef · DOI · Paper page
- Clarke G, 2009, Hum Psychopharmacol, 24, 217, 10.1002/hup.1008 · DOI
- 10.2165/11587620-000000000-00000 · DOI · Paper page
- 10.1017/S1461145707008206 · DOI · Paper page
- 10.1097/YIC.0b013e3282f1c1d8 · DOI · Paper page
- 10.1016/S0193-953X(18)30275-2 · DOI
- DGPPN, 2000, Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenhellkunde
- 10.2165/00019053-200725010-00003 · DOI · Paper page
- 10.4088/JCP.v68n0714 · DOI · Paper page
- 10.1017/S1461145710000015 · DOI · Paper page
- 10.4088/JCP.08m04309 · DOI · Paper page
- 10.1016/j.jad.2008.10.014 · DOI · Paper page
- 10.1176/appi.ps.56.8.1005 · DOI · Paper page
- 10.1007/s001150170045 · DOI
- 10.1002/da.20211 · DOI
- 10.1136/ebmh.6.4.105 · DOI
- 10.1192/bjp.bp.107.048504 · DOI · Paper page
- 10.1016/S1042-3680(02)00120-1 · DOI
- 10.1016/S0006-3223(00)01048-9 · DOI · Paper page
- 10.1176/ajp.154.12.1752 · DOI · Paper page
- 10.1016/j.euroneuro.2009.04.003 · DOI
- 10.1136/jnnp.23.1.56 · DOI · Paper page
- 10.1177/0269881107065738 · DOI · Paper page
- 10.3389/fnbeh.2011.00019 · DOI · Paper page
- Hunot V, 2007, Cochrane Database Syst Rev, CD001848
- 10.1590/S1516-44462004000300009 · DOI · Paper page
- Kasper S, 2007, CliniCum psy Sonderausgabe Jaenner
- 10.31887/DCNS.2008.10.4/kkelly · DOI · Paper page
- 10.1016/j.jad.2009.06.043 · DOI · Paper page
- 10.1016/j.jad.2009.06.039 · DOI · Paper page
- 10.1192/bjp.153.6.752 · DOI · Paper page
- 10.1017/S1092852900002248 · DOI
- 10.1097/00124509-200212000-00004 · DOI
- 10.1017/S1092852900018988 · DOI · Paper page
- Kupfer DJ, 1991, J Clin Psychiatry, 52, 28
- Lecrubier Y, 2007, J Clin Psychiatry, 68, 36
- 10.1002/da.20740 · DOI · Paper page
- 10.1016/S0893-133X(98)00075-X · DOI · Paper page
- 10.1016/j.biopsych.2008.05.034 · DOI · Paper page
- 10.1080/00048670701881587 · DOI · Paper page
- Martin JL, 2002, Cochrane Database Syst Rev, CD003493
- 10.1017/S1461145701002437 · DOI · Paper page
- 10.31887/DCNS.2008.10.4/jmendlewicz · DOI · Paper page
- 10.1080/15622970802503086 · doi:10.1080/15622970802503086
- 10.2165/11318630-000000000-00000 · DOI
- 10.1001/archpsyc.1992.01820100005001 · DOI · Paper page
- 10.1016/j.pnpbp.2007.09.004 · DOI
- 10.1016/j.euroneuro.2008.06.007 · DOI · Paper page
- 10.1192/bjp.134.4.382 · DOI · Paper page
- 10.1016/j.brs.2010.01.005 · DOI · Paper page
- 10.2174/138161208784480243 · DOI · Paper page
- Nelson J, 2008, Neuropsychiatr Dis Treat, 4, 937
- 10.1176/appi.ajp.2009.09030312 · DOI · Paper page
- 10.1176/ajp.2006.163.9.1519 · DOI · Paper page
- 10.1097/00004714-200302000-00013 · DOI · Paper page
- 10.1017/S1092852900003503 · DOI
- 10.1016/j.psc.2006.12.009 · DOI
- 10.1097/00124509-200403000-00004 · DOI · Paper page
- 10.1017/S1092852900003527 · DOI
- 10.1016/j.euroneuro.2008.08.009 · DOI · Paper page
- 10.1016/j.biopsych.2007.08.010 · DOI · Paper page
- 10.4088/JCP.v65n0212 · DOI · Paper page
- 10.4088/JCP.v68n0602 · DOI · Paper page
- 10.1097/01.jcp.0000169036.40755.16 · DOI · Paper page
- 10.1517/14656561003614781 · DOI · Paper page
- 10.1097/JCP.0b013e31818a6cea · DOI · Paper page
- 10.1016/0165-1781(90)90098-P · DOI · Paper page
- Richelson E, 2003, J Clin Psychiatry, 64, 5, 10.4088/JCP.v64n0301 · DOI · Paper page
- 10.1016/S0006-3223(02)01747-X · DOI
- 10.1016/j.biopsych.2005.05.025 · DOI · Paper page
- 10.1016/j.biopsych.2005.05.024 · DOI · Paper page
- 10.1176/appi.ajp.2011.10111645 · DOI · Paper page
- Rush AJ, 2009, CNS Drugs, 23, 627
- 10.1176/jnp.17.4.478 · DOI · Paper page
- 10.1097/00004714-199004000-00004 · DOI · Paper page
- 10.2174/187152707780363294 · DOI · Paper page
- 10.4088/PCC.v10n0302 · DOI · Paper page
- 10.1097/YIC.0b013e328014823d · DOI · Paper page
- 10.1007/978-3-211-78741-0_2 · DOI
- 10.3109/15622970903170835 · DOI · Paper page
- 10.1097/00001504-200401000-00004 · DOI
- 10.1016/S0140-6736(05)67582-4 · DOI
- Schmauss M, 2009, Fortschr Neurol Psychiatr, 77, 316, 10.1055/s-0028-1109338 · doi:10.1055/s-0028-1109338
- 10.2165/00003495-200868120-00002 · DOI
- 10.2165/11530280-000000000-00000 · DOI · Paper page
- 10.1111/j.1472-8206.2004.00195.x · DOI · Paper page
- SOPSI (1999) Società Italiana di Psicopatologia, Vol. 2010.
- 10.1016/S0924-977X(98)00004-2 · DOI · Paper page
- Souery D, 2006, J Clin Psychiatry, 67, 16, 10.4088/JCP.1106e16 · DOI · Paper page
- Stahl M, 2000, Essential Psychopharmacology: Neuroscientific Basis and Practical Applications
- 10.1017/S1092852900019726 · DOI · Paper page
- Thase ME, 1997, J Clin Psychiatry, 58, 23
- Thase ME, 2003, J Clin Psychiatry, 64, 3, 10.4088/JCP.v64n1116b · DOI
- Thase ME, 2008, Psychopharmacol Bull, 41, 58
- 10.1017/S1092852900003515 · DOI · Paper page
- 10.1097/YIC.0b013e3283277614 · DOI · Paper page
- 10.1002/mds.20963 · DOI · Paper page
- 10.1136/pgmj.59.690.229 · DOI
- 10.1007/s11920-007-0061-3 · DOI · Paper page
- 10.4088/JCP.v69n0908 · DOI · Paper page
- 10.1034/j.1600-0447.2000.102006454.x · DOI · Paper page
Cited by
Superolateral medial forebrain bundle deep brain stimulation in major depression: a gateway trial
Coenen, V. A., Bewernick, B. H., Kayser, S., Kilian, H., Boström, J., Greschus, S., Hurlemann, R., Klein, M. E., Spanier, S., Sajonz, B., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0369-9 · Cited by 176
Self-citationBewernick, B. H., Kayser, S., Gippert, S. M., Switala, C., Coenen, V. A., & Schlaepfer, T. E. (2017) · Brain stimulation · doi:10.1016/j.brs.2017.01.581 · Cited by 156
“In the TRD population, different ways of data analysis are suggested [22,23].”
MethodSelf-citationBartova, L., Dold, M., Kautzky, A., Fabbri, C., Spies, M., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., et al. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1635270 · Cited by 152
“This is of major importance for the clinical routine, where patients with TRD often remain misdiagnosed and subsequently undertreated (Fava and Davidson 1996; Schlaepfer et al. 2012), remaining under significant functional disability (Dunner et al. 2006; Amital et al. 2013; Kraus et al. 2017).”
BackgroundSelf-citationMillan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Negt, P., Brakemeier, E., Michalak, J., Winter, L., Bleich, S., & Kahl, K. G. (2016) · Brain and Behavior · doi:10.1002/brb3.486 · Cited by 126
Metadata
- Authors
- Schlaepfer, T. E., Ågren, H., Monteleone, P., Gasto, C., Pitchot, W., Rouillon, F., Nutt, D. J., & Kasper, S.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2012-01-11
- Volume
- 26
- Issue
- 5
- Pages
- 587-602
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2024465935
- Cited by
- 74
- References
- 42
- FWCI
- 7.85
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.